Boehringer Ingelheim and Simcere Forge US$1.26 B Collaboration to Advance Inflammatory Bowel Disease Bispecific Antibody

By Hitesh Udar

Pharma Deals Review: Vol 2026 Issue 2 (Table of Contents)

Published: 4 Feb-2026

DOI: 10.3833/pdr.v2026.i2.2996     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Boehringer Ingelheim and Simcere Pharmaceutical Group have entered into a global licensing and collaboration agreement granting Boehringer exclusive rights outside Greater China to develop, manufacture and commercialise SIM0709, a preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details